Is EXEL a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

2,517 people get EXEL articles and Market Currents by email alert.

Get email alerts on EXEL »

HEADLINES:

Exelixis' CEO Presents at UBS Global Healthcare Conference (Transcript)
Tue, May 21
Reminder: Cabozantinib to be Featured in Nine Presentations at the 2013 ASCO Annual Meeting

Business Wire (May 15, 2013)
Exelixis' CEO Presents at Bank of America Merrill Lynch Health Care Conference (Transcript)
Tue, May 14
Part 1: Will Array BioPharma Become A Late-Stage Biopharmaceutical Company?
C.R. Jackson • Sun, May 12 • 2 Comments
Exelixis Announces Webcasts of Upcoming Investor Conference Presentations

Business Wire (May 8, 2013)
Exelixis' CEO Discusses Q1 2013 Results - Earnings Call Transcript
Tue, May 7 • 1 Comment
Exelixis Announces First Quarter 2013 Financial Results

Business Wire (May 7, 2013)
Cabozantinib to be Featured in Nine Presentations at the 2013 ASCO Annual Meeting

Business Wire (May 7, 2013)
Exelixis Announces May 7th Webcast of First Quarter 2013 Financial Results Conference Call

Business Wire (Apr 17, 2013)
Cramer's Lightning Round- Kicking Myself Over Toll Brothers (4/16/13)
SA Editor Miriam Metzinger • Wed, Apr 17
Preclinical Data Presented at AACR Describe a Mechanism of Action of Cabozantinib in a Prostate Cancer Bone Metastasis Model

Business Wire (Apr 9, 2013)
Where Is Exelixis In The Cancer Therapeutics Market?
C.R. Jackson • Mon, Apr 1 • 8 Comments
Solving The R&D Investment Dilemma With Project Funding: Mark Kessel
Life Sciences Report • Sun, Mar 24 • 1 Comment
Exelixis Announces Webcast of March 4 Presentation at the 33rd Annual Cowen Health Care Conference

Business Wire (Feb 25, 2013)
Exelixis' CEO Discusses Q4 2012 Results - Earnings Call Transcript
Thu, Feb 21
Exelixis Selects Swedish Orphan Biovitrum AB as COMETRIQ™ European Distributor for Medullary Thyroid Cancer

Business Wire (Feb 21, 2013)
Exelixis Announces Fourth Quarter and Full Year 2012 Financial Results

Business Wire (Feb 21, 2013)
4 Biotech Stocks On The Clock
Stock Traders Daily • Tue, Feb 19
Exelixis Announces February 21st Webcast of Fourth Quarter and Full Year 2012 Financial Results Conference Call

Business Wire (Feb 7, 2013)
Exelixis Announces Webcast of February 12th Presentation at the 15th Annual BIO CEO & Investor Conference

Business Wire (Feb 6, 2013)

To learn more about Seeking Alpha Pro, click here.

Where Is Exelixis In The Cancer Therapeutics Market?
C.R. Jackson • Mon, Apr 1 • 8 Comments
Revisiting Exelixis And Cabozantinib
Brian L. Wilson • Wed, Jan 30 • 13 Comments
Exelixis Rebounds From 'Sell The News' Reaction
Brian L. Wilson • Mon, Dec 17, 2012 • 2 Comments
Exelixis's Promising Pipeline Of Drugs
Peter Geschek • Tue, Dec 4, 2012 • 8 Comments
Exelixis Traders Brace For Upcoming FDA Decision
Brian L. Wilson • Tue, Nov 27, 2012 • 8 Comments
Exelixis's Cabozantinib Should Receive FDA Approval, But Faces Long-Term Challenges
Beacon VP Investments • Mon, Nov 26, 2012 • 7 Comments
Exelixis Stock Treads Water Ahead Of FDA Decision
Brian L. Wilson • Fri, Oct 26, 2012 • 11 Comments
ArQule's Tivantinib Failure And Exelixis' Cabozantinib PDUFA: Is There A Correlation?
Chemistfrog • Fri, Oct 12, 2012 • 9 Comments
Exelixis: First Partnered Program Enters Phase III
Ohad Hammer • Wed, Oct 3, 2012 • 8 Comments
Why The Exelixis Offering Makes Sense
Brian L. Wilson • Tue, Aug 14, 2012 • 6 Comments
Can Exelixis Continue Making Big Moves?
Brian L. Wilson • Wed, Jul 11, 2012 • 1 Comment
Exelixis: A Standout Pick For Upcoming ASCO Week
Brian L. Wilson • Thu, May 31, 2012
Exelixis: Uncovering Value
David Sobek • Mon, Apr 30, 2012 • 8 Comments
Exelixis' Dance With Big Pharma Continues
M. E. Garza • Wed, Dec 21, 2011 • 1 Comment
Exelixis: Setting The Facts Straight
Ohad Hammer • Mon, Nov 7, 2011 • 14 Comments
Exelixis Fights City Hall, and City Hall Looks To Be Winning
Derek Lowe • Wed, Nov 2, 2011 • 2 Comments
Exelixis' Curious And Risky Strategy
Stephen Simpson • Tue, Nov 1, 2011 • 14 Comments
Exelixis: Still Promising, Still Controversial
Ohad Hammer • Mon, Aug 22, 2011 • 6 Comments
Biotech Gem Exelixis Is Compelling Only for the Long Term
Jonathan Faison • Fri, Aug 19, 2011 • 3 Comments
Exelixis: Looming Cancer Conference a Favorable Swing Trade Opportunity
Michael Kudrna • Mon, May 16, 2011 • 11 Comments

Part 1: Will Array BioPharma Become A Late-Stage Biopharmaceutical Company?
C.R. Jackson • Sun, May 12 • 2 Comments
Cramer's Lightning Round- Kicking Myself Over Toll Brothers (4/16/13)
SA Editor Miriam Metzinger • Wed, Apr 17
Solving The R&D Investment Dilemma With Project Funding: Mark Kessel
Life Sciences Report • Sun, Mar 24 • 1 Comment
4 Biotech Stocks On The Clock
Stock Traders Daily • Tue, Feb 19
3 Highly Shorted Stocks Under $5 Being Snapped Up By Hedge Funds
Kapitall • Tue, Jan 15
Biotech Portfolio Update: 2012 Summary And 2013 Outlook
Ohad Hammer • Mon, Dec 24, 2012 • 11 Comments
5 Medical Stock Losers From Last Week With High Short Ratios
Heisenberg Principle • Sat, Dec 22, 2012 • 14 Comments
Aveo Pharmaceuticals: A Hidden Gem Or A Hidden Disaster
John Li • Mon, Dec 10, 2012 • 7 Comments
Biotech Weekly Recap: The Market Holds While Biotech Crumbles
Brian L. Wilson • Sun, Dec 9, 2012 • 6 Comments
Acadia Pharmaceuticals: Making Big Waves
Efsinvestment • Fri, Dec 7, 2012 • 2 Comments
VIX - Options Volatility Sonar: Wednesday Recap
Erick McKitterick • Wed, Dec 5, 2012 • 4 Comments
The Road Toward Far-Reaching Therapeutics Through Illumina, Sarepta
Prohost Biotech • Tue, Dec 4, 2012 • 3 Comments
Biotech Weekly Recap: Loads Of Bullishness, 2 Giant Rallies, And Selling
Brian L. Wilson • Sun, Dec 2, 2012 • 19 Comments
Prostate Cancer Market Takes Shape - Part 2: Treatments In Clinical Development
LifeSci Advisors • Thu, Nov 29, 2012 • 3 Comments
Cramer's Lightning Round - American Tower Is One Of The Best Stories Out There (11/26/12)
SA Editor Miriam Metzinger • Tue, Nov 27, 2012 • 1 Comment
Wednesday's Bio-Pharma Catalyst Trades And Watch List
Scott Matusow • Wed, Nov 21, 2012 • 8 Comments
Cramer's Lightning Round - Qualcomm Is Finally Getting Respect (11/13/12)
SA Editor Miriam Metzinger • Wed, Nov 14, 2012 • 8 Comments
Biotech Catalyst Calendar - 4 Stocks To Watch In November
LifeSci Advisors • Wed, Nov 7, 2012 • 11 Comments
3 November Catalysts For Biotech Traders
Brian L. Wilson • Tue, Nov 6, 2012 • 4 Comments
3 Companies With Promising New Cancer Treatments
The Swiss Trader • Tue, Oct 23, 2012 • 3 Comments

Exelixis' CEO Presents at UBS Global Healthcare Conference (Transcript)
Tue, May 21
Exelixis' CEO Presents at Bank of America Merrill Lynch Health Care Conference (Transcript)
Tue, May 14
Exelixis' CEO Discusses Q1 2013 Results - Earnings Call Transcript
Tue, May 7 • 1 Comment
Exelixis' CEO Discusses Q4 2012 Results - Earnings Call Transcript
Thu, Feb 21
Exelixis' CEO Presents at J.P. Morgan 31st Annual Healthcare Conference (Transcript)
Wed, Jan 9
Exelixis' CEO Hosts Announcement of EMA Acceptance of Marketing Authorization Application for COMETRIQ - (Transcript)
Fri, Nov 30, 2012 • 1 Comment
Exelixis' CEO Presents at Credit Suisse Group AG Healthcare Conference (Transcript)
Thu, Nov 15, 2012 • 1 Comment
Exelixis' Management Presents at Lazard Capital Markets 9th Annual Healthcare Conference (Transcript)
Wed, Nov 14, 2012 • 2 Comments
Exelixis' CEO Discusses Q3 2012 Results - Earnings Call Transcript
Wed, Nov 7, 2012
Exelixis' CEO Presents at Morgan Stanley Global Healthcare Conference (Transcript)
Tue, Sep 11, 2012
Exelixis' CEO Discusses Q2 2012 Results - Earnings Call Transcript
Thu, Aug 2, 2012 • 3 Comments
Exelixis CEO Presents at Goldman Sachs Healthcare Conference (Transcript)
Wed, Jun 6, 2012 • 2 Comments
Exelixis' Management Presents at Bank of America Merrill Lynch 2012 Health Care Conference (Transcript)
Thu, May 17, 2012
Exelixis' Management Presents at Deutsche Bank Securities Annual Health Care Conference (Transcript)
Wed, May 9, 2012
Exelixis's CEO Discusses Q1 2012 Results - Earnings Call Transcript
Thu, May 3, 2012
Exelixis' CEO Presents at Lazard Capital Market 8th Annual Healthcare Conference (Transcript)
Tue, Mar 13, 2012
Exelixis' CEO Presents at 30th Annual JPMorgan Healthcare Conference - Conference Call Transcript
Fri, Mar 9, 2012
Exelixis' CEO Presents at Citi Global Health Care Conference (Transcript)
Tue, Feb 28, 2012
Exelixis' CEO Discusses Q4 2011 Results - Earnings Call Transcript
Wed, Feb 8, 2012
Exelixis Management Hosts Analyst Day - Conference Call Transcript
Sat, Dec 3, 2011

Reminder: Cabozantinib to be Featured in Nine Presentations at the 2013 ASCO Annual Meeting

Business Wire (May 15, 2013)
Exelixis Announces Webcasts of Upcoming Investor Conference Presentations

Business Wire (May 8, 2013)
Exelixis Announces First Quarter 2013 Financial Results

Business Wire (May 7, 2013)
Cabozantinib to be Featured in Nine Presentations at the 2013 ASCO Annual Meeting

Business Wire (May 7, 2013)
Exelixis Announces May 7th Webcast of First Quarter 2013 Financial Results Conference Call

Business Wire (Apr 17, 2013)
Lightning Round: Dollar Tree, Toll Brothers & More

at CNBC.com (Apr 16, 2013)
Preclinical Data Presented at AACR Describe a Mechanism of Action of Cabozantinib in a Prostate Cancer Bone Metastasis Model

Business Wire (Apr 9, 2013)
Exelixis Announces Webcast of March 4 Presentation at the 33rd Annual Cowen Health Care Conference

Business Wire (Feb 25, 2013)
Exelixis Selects Swedish Orphan Biovitrum AB as COMETRIQ™ European Distributor for Medullary Thyroid Cancer

Business Wire (Feb 21, 2013)
Exelixis Announces Fourth Quarter and Full Year 2012 Financial Results

Business Wire (Feb 21, 2013)
Exelixis Announces February 21st Webcast of Fourth Quarter and Full Year 2012 Financial Results Conference Call

Business Wire (Feb 7, 2013)
Exelixis Announces Webcast of February 12th Presentation at the 15th Annual BIO CEO & Investor Conference

Business Wire (Feb 6, 2013)
Exelixis Announces COMETRIQ™ (cabozantinib) Is Now Available in the U.S.

Business Wire (Jan 24, 2013)
Exelixis Announces Webcast of January 9 Presentation at the J.P. Morgan 31st Annual Healthcare Conference

Business Wire (Dec 13, 2012)
Health-care Stocks: HMA’s pre-emptive strike against ‘60 Minutes’

at MarketWatch.com (Nov 30, 2012)
Midday Movers: HNZ, CAG, RAH & More

at CNBC.com (Nov 30, 2012)
Exelixis Announces EMA Acceptance of Marketing Authorization Application For COMETRIQ™ (cabozantinib)

Business Wire (Nov 29, 2012)
FDA Approves COMETRIQ™ (Cabozantinib) for Treatment of Progressive, Metastatic Medullary Thyroid Cancer

Business Wire (Nov 29, 2012)
Lightning Round: Abercrombie & Fitch, Research In Motion, & More

at CNBC.com (Nov 27, 2012)
Lightning Round: American Tower, Sprint, Nvidia & More

at CNBC.com (Nov 26, 2012)

EXEL vs. ETF Alternatives

Company Description

BUSINESS

Overview

We are committed to discovering, developing and commercializing innovative therapies for the treatment of cancer and other serious diseases. Through our integrated drug discovery and development activities, we are building a portfolio of novel compounds that we believe... More

Sector: Healthcare

Industry: Biotechnology

Country: United States

TruffelPig
$EXEL - this is the probably dumbest analysis I ever read on a biotech spec stock: http://bit.ly/XimHOl
Feb 27, 11:43 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

BlackRook
$EXEL crosses 200 dma. Cometriq to be available 'soon...'
Jan 9, 3:29 PM
Reply (1)

• !Report Abuse
View all 1 replies
BlackRook: ...and wets itself at JPM.
Jan 10, 10:22 AM
• !Report Abuse
Add a reply...

140 characters

eccw
whats this week going to look like for $EXEL ? post approval sell-off seems pretty dire. at $4.30 attractive?
12/10/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

BlackRook
$EXEL "off label" for men with very late stage, metastatic, and chemotherapy-resistant prostate cancer too.' http://bit.ly/YeLINU
11/30/12
Reply (2)

• !Report Abuse
View all 2 replies
Maria Auziliadora: that's pretty good thank's for the I see this one going higher
11/30/12
• !Report Abuse
BlackRook: You're welcome.
11/30/12
• !Report Abuse
Add a reply...

140 characters

nsahbti
Buying more $EXEL, this is bigger than approval: http://1.usa.gov/TtVns9 Bigger population
11/30/12
Reply (1)

• !Report Abuse
View all 1 replies
Maria Auziliadora: thank's for the link I am adding more also
11/30/12
• !Report Abuse
Add a reply...

140 characters

nsahbti
Rally or sell off? Will $EXEL rally up to the 7's or will the post approval sell off begin?
11/29/12
Reply (6)

• !Report Abuse
View all 6 replies
nsahbti: They don't know they cant
11/30/12
• !Report Abuse
Maria Auziliadora: i guess they don't believe in death lol
11/30/12
• !Report Abuse
Add a reply...

140 characters

BlackRook
$EXEL- MTC is a relatively small market. The scope in this trial scheduled to complete next month, is huge. http://1.usa.gov/TtVns9
11/29/12
Reply (1)

• !Report Abuse
View all 1 replies
BlackRook: Off-Label Drug Use: What You Need to Know http://on.webmd.com/11q6yru
11/30/12
• !Report Abuse
Add a reply...

140 characters

Maria Auziliadora
$EXEL HALTED
11/29/12
Reply (3)

• !Report Abuse
View all 3 replies
Maria Auziliadora: I know it is rdiculous but big companies can buy this one out easily
11/29/12
• !Report Abuse
Maria Auziliadora: for the moment JM
12/2/12
• !Report Abuse
Add a reply...

140 characters

Jason F
My thoughts on $EXEL chart http://stks.co/cEw8
11/28/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Chemistfrog
EXEL should start getting a lot of serious attention going into 11/29 PDUFA cabozantinib. Priority review.. $EXEL
9/28/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

BlackRook
$EXEL crosses 200 dma. Cometriq to be available 'soon...'
Jan 9, 3:29 PM
Reply (1)

• !Report Abuse
View all 1 replies
BlackRook: ...and wets itself at JPM.
Jan 10, 10:22 AM
• !Report Abuse
Add a reply...

140 characters

Maria Auziliadora
$EXEL HALTED
11/29/12
Reply (3)

• !Report Abuse
View all 3 replies
Maria Auziliadora: I know it is rdiculous but big companies can buy this one out easily
11/29/12
• !Report Abuse
Maria Auziliadora: for the moment JM
12/2/12
• !Report Abuse
Add a reply...

140 characters

BlackRook
$EXEL "off label" for men with very late stage, metastatic, and chemotherapy-resistant prostate cancer too.' http://bit.ly/YeLINU
11/30/12
Reply (2)

• !Report Abuse
View all 2 replies
Maria Auziliadora: that's pretty good thank's for the I see this one going higher
11/30/12
• !Report Abuse
BlackRook: You're welcome.
11/30/12
• !Report Abuse
Add a reply...

140 characters

nsahbti
Buying more $EXEL, this is bigger than approval: http://1.usa.gov/TtVns9 Bigger population
11/30/12
Reply (1)

• !Report Abuse
View all 1 replies
Maria Auziliadora: thank's for the link I am adding more also
11/30/12
• !Report Abuse
Add a reply...

140 characters

nsahbti
Rally or sell off? Will $EXEL rally up to the 7's or will the post approval sell off begin?
11/29/12
Reply (6)

• !Report Abuse
View all 6 replies
nsahbti: They don't know they cant
11/30/12
• !Report Abuse
Maria Auziliadora: i guess they don't believe in death lol
11/30/12
• !Report Abuse
Add a reply...

140 characters

BlackRook
$EXEL- MTC is a relatively small market. The scope in this trial scheduled to complete next month, is huge. http://1.usa.gov/TtVns9
11/29/12
Reply (1)

• !Report Abuse
View all 1 replies
BlackRook: Off-Label Drug Use: What You Need to Know http://on.webmd.com/11q6yru
11/30/12
• !Report Abuse
Add a reply...

140 characters

TruffelPig
GERN has left my portfolio.....so sick of this company.....sold with loss. Bought EXEL.
8/9/12
Reply (3)

• !Report Abuse
View all 3 replies
TruffelPig: Not sure - GERN had a hug he run up but EXEL is probably better anyhow.
9/9/12
• !Report Abuse
TruffelPig: EXEL will have a product soon on the market - GERN after xxxxxxxxx years Phase II again.........
9/9/12
• !Report Abuse
Add a reply...

140 characters

lewwillis
Thanks to TruffelPig for the intro to EXEL. Nice pick!
8/29/12
Reply (1)

• !Report Abuse
View all 1 replies
nsahbti: Whats the target price approaching PDUFA in November?
8/29/12
• !Report Abuse
Add a reply...

140 characters

Joe Springer
Sell Spectrum! http://seekingalpha.com/a/hmw5 $SPPI $OMPI $ALTH $BMY $BIIB $UHS $WCG $CYH $TARO $PDLI $EXEL #biotech #pharma #drugs #stocks
8/23/12
Reply (5)

• !Report Abuse
View all 5 replies
phemale60: not that sophisticated - just trade. I do alright tho for a newbie. I'll learn on my next vaca - sit and read. Then I'll know! ;-/
8/23/12
• !Report Abuse
Joe Springer: : )
8/23/12
• !Report Abuse
Add a reply...

140 characters

TruffelPig
Anyone any idea why there is this huge volume in EXEL today? 30% of all shares.....
8/9/12
Reply (2)

• !Report Abuse
View all 2 replies
Dr. Kris: An HFT short squeeze? The volume has been ramping up for a week.
8/9/12
• !Report Abuse
TruffelPig: Well, at least that way the dilution is out of the way :). Time to get long.
8/9/12
• !Report Abuse
Add a reply...

140 characters

TruffelPig
Sold $4 Nov puts on EXEL for 0.75 - same day the FDA review will come ;P
8/9/12
Reply (1)

• !Report Abuse
View all 1 replies
TruffelPig: Coincidence :) but useful.
8/9/12
• !Report Abuse
Add a reply...

140 characters

TruffelPig
EXEL being whipped on secondary even though FDA review for MTC drug on Nov. 17 likely great!
8/6/12
Reply (7)

• !Report Abuse
View all 7 replies
TruffelPig: Hehehe, don't blame me if it doesn't work out. However, I think this will be a winner.
8/6/12
• !Report Abuse
kevin1533: Haha ive been following this for a while. was waiting for an entry point
8/6/12
• !Report Abuse
Add a reply...

140 characters

freefdawatchlist
http://bit.ly/KW1sxj Earnings after hours: $AIG $BEBE, $BODY $CADX $CNQ $CF $DOLE $EXEL $ISTA $MDLZ $KOG $LNKD $SD $SPRD $SQNM $ZAG
5/3/12
Reply (3)

• !Report Abuse
View all 3 replies
cn_habs: NES is up 12% in AH yet missed earnings...
5/3/12
• !Report Abuse
freefdawatchlist: AIG is down 2%, LNKD is up
5/3/12
• !Report Abuse
Add a reply...

140 characters

Kinetic Investments
$EXEL up 8% after pricing of offering - http://seekingalpha.com/a/7o73
2/10/12
Reply (1)

• !Report Abuse
View all 1 replies
Kinetic Investments: $EXEL - Make that 10.5%
2/10/12
• !Report Abuse
Add a reply...

140 characters

Chemistfrog
Loving oversold biotechs that haven't "caught back up" yet: CRMD, CTSO.OB, PPHM, BIOD, DCTH, CLSN, CRIS, LPTN and EXEL.
12/3/11
Reply (3)

• !Report Abuse
View all 3 replies
Chemistfrog: CC is Tues, I bought in case they have good news about licensing or resuming their program I'll sell on spike. If no news at CC dump it..
12/5/11
• !Report Abuse
Sakoku: nice spike
12/7/11
• !Report Abuse
Add a reply...

140 characters

EXEL Exelixis, Inc.

EXEL

Exelixis, Inc.